60772-67-0

Basic information

• Product Name: 3-ISOPROPOXYBENZOIC ACID
• Synonyms: AKOS BB-8626;AKOS BB/0141;3-ISOPROPOXYBENZOIC ACID;CHEMBRDG-BB 4402367;BUTTPARK 154\04-18;ASISCHEM T31123;TIMTEC-BB SBB001905;3-isopropoxybenzoic acid(SALTDATA: FREE)
• CAS NO: 60772-67-0
• Molecular Formula: C₁₀H₁₂O₃
• Molecular Weight: 180.2
• Mol File: 60772-67-0.mol

Chemical Properties

• Melting Point: 96-97°C
• Boiling Point: 310.4 °C at 760 mmHg
• Flash Point: 121.9 °C
• Appearance: /
• Density: 1.13 g/cm³
• Vapor Pressure: 0.000259mmHg at 25°C
• Refractive Index: 1.528
• Storage Temp.: Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: pK1:4.15 (20°C)
• CAS DataBase Reference: 3-ISOPROPOXYBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-ISOPROPOXYBENZOIC ACID(60772-67-0)
• EPA Substance Registry System: 3-ISOPROPOXYBENZOIC ACID(60772-67-0)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 60772-67-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-Isopropoxybenzoic acid is used as a reagent in organic synthesis for the preparation of a wide range of chemical compounds. Its unique structure allows for selective reactions and functional group transformations, facilitating the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3-isopropoxybenzoic acid is utilized as a key intermediate in the synthesis of various drug molecules. Its ability to form diverse chemical linkages and its compatibility with a range of reaction conditions make it a valuable component in the development of new medications.
Used in Chemical Processes:
3-Isopropoxybenzoic acid is also employed in various chemical processes, such as the production of specialty chemicals, agrochemicals, and other industrial applications. Its stability and reactivity contribute to the efficiency and effectiveness of these processes, leading to improved product yields and quality.

InChI:InChI=1/C10H12O3/c1-7(2)13-9-5-3-4-8(6-9)10(11)12/h3-7H,1-2H3,(H,11,12)

Upstream product

• 19438-10-9 methyl 3-hydroxybenzoate 
• 350989-42-3 methyl 3-isopropoxybenzoate 
• 75-30-9 2-iodo-propane 
• 99-06-9 3-Carboxyphenol 
• 584-08-7 potassium carbonate 
• 78-93-3 butanone 
• 56-23-5 tetrachloromethane 
• 53631-77-9 3-hydroxybenzoic acid 1-methylethyl ester 
• 7637-07-2 boron trifluoride 
• 187737-37-7 propene 
• 75-29-6 isopropyl chloride 

Downstream Products

• 1005786-44-6 N-[3-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)phenyl]-3-isopropoxybenzamide 
• 666859-00-3 N-[4-BROMO-2-(5-OXO-4, 5-DIHYDRO-1, 2,4-oxadiazol-3-yl) PHENYL]-3-isopropoxybenzamide 
• 130110-77-9 2-Chloro-3',4-di-isopropoxy-2'-methylthiostilbene 
• 130110-75-7 2-Chloro-3',4-di-isopropoxy-2'-methylthiostilbene 
• 130110-67-7 2-(3-Isopropoxy-2-methylthiophenyl)-4,4-dimethyl-4,5-dihydro-oxazole 
• 130110-66-6 2-(3-Isopropoxyphenyl)-4,4-dimethyl-4,5-dihydro-oxazole 
• 130110-68-8 Methyl 3-isopropoxy-2-methylthiobenzoate 
• 130110-70-2 3-Isopropoxy-2-methylthiobenzyl chloride 
• 130110-69-9 3-Isopropoxy-2-methylthiophenylmethanol 

Relevant articles and documents

Demonstrating Ligandability of the LC3A and LC3B Adapter Interface

Autophagy is the common name for a number of lysosome-based degradation pathways of cytosolic cargos. The key components of autophagy are members of Atg8 family proteins involved in almost all steps of the process, from autophagosome formation to their selective fusion with lysosomes. In this study, we show that the homologous members of the human Atg8 family proteins, LC3A and LC3B, are druggable by a small molecule inhibitor novobiocin. Structure-activity relationship (SAR) studies of the 4-hydroxy coumarin core scaffold were performed, supported by a crystal structure of the LC3A dihydronovobiocin complex. The study reports the first nonpeptide inhibitors for these protein interaction targets and will lay the foundation for the development of more potent chemical probes for the Atg8 protein family which may also find applications for the development of autophagy-mediated degraders (AUTACs).

S1P1 AGONIST AND APPLICATION THEREOF

The present invention relates to a class of tricyclic compounds and an application thereof as a sphingosine 1-phosphate type 1 (S1P1) receptor agonist. The invention specifically relates to a compound represented by formula (II), and a tautomer and pharmaceutically acceptable salt of same.

ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES

The present invention relates to anilinopyrazole compounds of formula (1) in which R3 represents an aromatic 5- or 6-membered heteroaromatic ring which is optionally fused to phenyl, said heterocycle or fused heterocycle is optionally substituted, X represents a carboxylic acid, ester or amide, or sulfonamide, and the remaining groups are as defined in the text. It also relates to pharmaceutical compositions containing these materials and, and methods for treating diabetes and related disorders using these materials.

SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES

The present invention relates to substituted pyrrolidinyl-3-yl-alkyl-piperidines, their stereoisomers, and pharmaceutically acceptable salts thereof and processes for preparation of the same. The compounds of the present invention are useful in their pharmacological activities such as tachykinin antagonism, especially substance P and neurokinin A antagonism, and the like. Compounds having the property of tachykinin antagonism are indicated for conditions associated with neurogenic inflammation and other diseases described herein.